Source: Annual Congress 2001 - Disease of the pulmonary circulation

Abstract

Pulmonary complications (PC) of infective endocarditis (IE) in intravenous drug users may resemble variety of diseases and result from systemic effects of infection, metastatic foci and emboli. Among 60 intravenous drug users with IE PC were revealed in 72%. The pulmonary symptoms included cough (32%), dyspnoe (28%), hemophtysis (23%), chest pain (20%). Pulmonary onset of IE leaded to diagnostic mistakes in 12% patients. Early clinical symptoms in pulmonary onset of IE were fever (100%), cough (47%), dyspnoe (32%), chest pain (23%). Pulmonary complications of IE in intravenous drug users included pneumonia in 72%, pleuritis in 33%, hydrothorax in 13%, lung abscess in 13% patients. Pulmonary insufficiency was in 60% patients. Vegetations were found on transthoracic echocardiography in 86% patients with PC, tricuspid valve was affected in 92% patients. The leading causative agents of IE with PC were staphylococci (78%). Pulmonary emboli or pneumonia are common complications of IE in intravenous drug users. The knowledge of PC of IE in intravenous drug users is important for early diagnostics and treatment.

Rating:

Share or cite this content

Citations should be made in the following way:
A. A. Demin, V. P. Drobysheva, O. Y. Welter (Novosibirsk, Russia). Pulmonary complications of infective endocarditis in intravenous drug users. Eur Respir J 2001; 16: Suppl. 31, 3511

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary onset and complications of intravenous drug users infective endocarditis Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018 Lung injury in intravenous drug users with infective endocarditis Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Pulmonary hypertension in patients with infective endocarditis Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Septic pulmonary embolism in intravenous drug users. Source: International Congress 2017 – Pulmonary embolism Year: 2017 Pulmonary pathology in fatal intravenous heroin addicts Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003 Pleuropulmonary manifestations of infective endocarditis Source: Eur Respir J 2003; 22: Suppl. 45, 47s Year: 2003 Uncommon pulmonary complications of inhaled cannabinoide Source: Eur Respir J 2004; 24: Suppl. 48, 537s Year: 2004 Systemic corticosteroid and inhalation corticosteroid therapy are associated with nontuberculous mycobacterial pulmonary disease Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 Comparison of two regimens of oral anticoagulation in pulmonary embolism Source: Eur Respir J 2006; 28: Suppl. 50, 632s Year: 2006 Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Severe respiratory illness in an intravenous drug abuser Source: ISSN=ISSN 1810-6838, ISBN=, page=207 Year: 2006 Pulmonary complications in severe malaria Source: Eur Respir J 2003; 22: Suppl. 45, 451s Year: 2003 The use of perioperative intravenous sildenafil in patients with mitral valve disease and co-existent pulmonary hypertension during cardiac surgery Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Pulmonary infections in neutropenic patients Source: Eur Respir J 2003; 22: Suppl. 45, 334s Year: 2003 Pulmonary complications of HIV infection Source: Annual Congress 2007 - ACCP 2 - Pulmonary complications of HIV infection Year: 2007 Broviac catheter complications of intravenous epoprostenol therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 636s Year: 2004 Complications of anticoagulant therapy in patients with pulmonary thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 604s Year: 2007 High incidence of bacteraemia complicating iv prostaglandin therapy in patients with pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 371s Year: 2002 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014